Skip to main content


Page 11 of 12

  1. Recently the sequencing of the human genome has become a major biological and clinical research field. However, the public health impact of this new technology with focus on the financial effect is not yet to ...

    Authors: Martin Frank, Anne Prenzler, Roland Eils and J-Matthias Graf von der Schulenburg
    Citation: Health Economics Review 2013 3:29
  2. The objective of the study was to analyse whether azacitidine is a cost-effective option for the treatment of myelodysplastic syndrome in the Spanish setting compared with conventional care regimens, including...

    Authors: Carlos Crespo, Estela Moreno, Jordi Sierra, Suzan Serip and Marta Rubio
    Citation: Health Economics Review 2013 3:28
  3. Rotavirus gastroenteritis (RVGE) is a frequent disease in young children. The recommended German paediatric immunisation schedule does not currently include rotavirus vaccination. A lack of economic data on th...

    Authors: Stefanie Knoll, Christoph Mair, Ursula Benter, Katja Vouk and Baudouin Standaert
    Citation: Health Economics Review 2013 3:27
  4. Respiratory syncytial virus (RSV) is a common cause of respiratory infection that is highly prevalent in infants. Severe cases of RSV infection require hospitalisation; this is most likely to occur in infant p...

    Authors: Anthony Bentley, Ivana Filipovic, Katherine Gooch and Katharina Büsch
    Citation: Health Economics Review 2013 3:18
  5. Fingolimod is an innovative drug with a significant budget impact in the treatment of MS in Spain. The aim of this study was to calculate the direct cost comparison of glatiramer acetate and fingolimod for the...

    Authors: Rainel Sanchez-de la Rosa, Eliazar Sabater and Miguel A Casado
    Citation: Health Economics Review 2013 3:13
  6. The reliance on out-of-pocket payments for health services leads to a catastrophic burden for many households in Bangladesh. The World Health Organization suggests that risk-pooling mechanisms should be used f...

    Authors: Jahangir AM Khan and Sayem Ahmed
    Citation: Health Economics Review 2013 3:12
  7. The increasing prevalence of diabetes and its inadequate management results in a heavy burden of the disease for the patients, the health and the productive system and the overall community. Consequently, it i...

    Authors: Jorge F Elgart, Joaquin E Caporale, Lorena Gonzalez, Eleonora Aiello, Maximiliano Waschbusch and Juan J Gagliardino
    Citation: Health Economics Review 2013 3:11
  8. Myocardial infarction networks have been shown to improve guideline adherent therapy and outcomes in patients presenting with acute ST-elevation myocardial infarction (STEMI). Our objective was to assess the s...

    Authors: Ralf Birkemeyer, Anke Dauch, Alfred Müller, Manfred Beck, Henrik Schneider, Hueseyin Ince, Werner Jung and Steffen Wahler
    Citation: Health Economics Review 2013 3:10
  9. In contrast to other countries, surgery still represents the common invasive treatment for varicose veins in Germany. However, radiofrequency ablation, e.g. ClosureFast, becomes more and more popular in other ...

    Authors: Alexander Kuhlmann, Anne Prenzler, Jan Hacker and J-Matthias Graf von der Schulenburg
    Citation: Health Economics Review 2013 3:9
  10. Common approaches in cost-effectiveness analyses do not adjust for confounders. In nonrandomized studies this can result in biased results. Parametric models such as regression models are commonly applied to a...

    Authors: Tommi Härkänen, Timo Maljanen, Olavi Lindfors, Esa Virtala and Paul Knekt
    Citation: Health Economics Review 2013 3:8
  11. To examine the impact of temporary and permanent weight loss of 10% and 15% on 10-year and lifetime Medicare spending among adults with overweight and obesity aged 65 years and older. Weight loss of this magni...

    Authors: Kenneth E Thorpe, Zhou Yang, Kathleen M Long and W Timothy Garvey
    Citation: Health Economics Review 2013 3:7
  12. This study aimed to apply the previously validated severity index for rheumatoid arthritis (SIFRA) to prevalent rheumatoid arthritis (RA) groups in Turkey and determine the effect of RA severity on health care...

    Authors: Onur Baser, Erdem Baser, Akif Altinbas and Abdulkadir Burkan
    Citation: Health Economics Review 2013 3:5
  13. Icatibant is the only subcutaneous treatment for acute Type I and Type II hereditary angioedema with C1-esterase inhibitor deficiency (HAE-C1-INH) licensed for self-administration in Europe.

    Authors: Antonio J Blasco, Pablo Lázaro, Teresa Caballero and Mar Guilarte
    Citation: Health Economics Review 2013 3:2
  14. Health care expenditure has been low over the years in developing regions of the world. A majority of countries in these regions, especially sub-Saharan Africa (SSA), rely on donor grants and loans to finance ...

    Authors: Jacob Novignon, Solomon A Olakojo and Justice Nonvignon
    Citation: Health Economics Review 2012 2:22
  15. To obtain detailed real-life data on costs and dosing patterns in the utilisation of the TNF inhibitors adalimumab, etanercept, and infliximab in patients treated in Switzerland.

    Authors: Jan Zeidler, Thomas Mittendorf, Rüdiger Müller and Johannes von Kempis
    Citation: Health Economics Review 2012 2:20
  16. Persistent infections with human papillomavirus (HPV) are a necessary cause of cervical cancer and are responsible for important morbidity in men and women. Since 2007, HPV vaccination has been recommended and...

    Authors: Deniz Schobert, Vanessa Remy and Oliver Schoeffski
    Citation: Health Economics Review 2012 2:19
  17. Cost-of-illness studies (COI) can identify and measure all the costs of a particular disease, including the direct, indirect and intangible dimensions. They are intended to provide estimates about the economic...

    Authors: Nagede Costa, Helene Derumeaux, Thomas Rapp, Valérie Garnault, Laura Ferlicoq, Sophie Gillette, Sandrine Andrieu, Bruno Vellas, Michel Lamure, Alain Grand and Laurent Molinier
    Citation: Health Economics Review 2012 2:18
  18. It is acknowledged that economic evaluation methods as they have been developed for Health Technology Assessment do not capture all the costs and benefits relevant to the assessment of public health interventi...

    Authors: Kevin Marsh, Ceri J Phillips, Richard Fordham, Evelina Bertranou and Janine Hale
    Citation: Health Economics Review 2012 2:17
  19. The lower sales price of generic lamivudine has caused healthcare administrators to consider abolishing fixed-dose antiretroviral combinations (FDCs) that contain lamivudine and emtricitabine. The alternative ...

    Authors: Francesc Homar, Virginia Lozano, Juan Martínez-Gómez, Itziar Oyagüez, Antonio Pareja, Antoni Payeras, Joaquín Serrano, Carmen Carratalá and Miguel Ángel Casado
    Citation: Health Economics Review 2012 2:16
  20. Prepayments and risk pooling through social health insurance has been advocated by international development organizations. Social health insurance is seen as a mechanism that helps mobilize resources for heal...

    Authors: Philip Ayizem Dalinjong and Alexander Suuk Laar
    Citation: Health Economics Review 2012 2:13
  21. Osteoporotic fractures impose a huge economic burden on society. Though several cost of illness studies from other countries exist, no equivalent study has been conducted in Austria. Our study aims at assessin...

    Authors: Hans Peter Dimai, Kurt Redlich, Monika Peretz, Fredrik Borgström, Uwe Siebert and Jörg Mahlich
    Citation: Health Economics Review 2012 2:12
  22. An understanding of the complex relationship between health status and welfare is crucial for critical policy interventions. However, the focus of most policies in developing regions has been on current welfar...

    Authors: Jacob Novignon, Justice Nonvignon, Richard Mussa and Levison S Chiwaula
    Citation: Health Economics Review 2012 2:11
  23. We propose simple modifications for the Kakwani tax progressivity measure that make it suitable for evaluating access inequality for medical services. Our modification is to measure inequality using the ratio ...

    Authors: Mototsugu Fukushige, Noriko Ishikawa and Satoko Maekawa
    Citation: Health Economics Review 2012 2:10
  24. The aim of the study was to determine the costs of treating schizophrenia from the perspective of the statutory health insurance, as well as the identification of predictors of hospitalisation of formerly stab...

    Authors: Jan Zeidler, Lara Slawik, Jochen Fleischmann and Wolfgang Greiner
    Citation: Health Economics Review 2012 2:9
  25. Physician ownership of in-office ancillary services (IOASs) has come under increasing scrutiny. Advocates of argue that IOASs allow physicians to supervise the quality and coordination of care. Critics have ar...

    Authors: John E Schneider, Robert L Ohsfeldt, Cara M Scheibling and Sarah A Jeffers
    Citation: Health Economics Review 2012 2:7
  26. Community-Based Health Insurance (CBHI) is an emerging concept for providing financial protection against the cost of illness and improving access to quality health services for low-income rural households who...

    Authors: Hermann Pierre Pythagore Donfouet and Pierre-Alexandre Mahieu
    Citation: Health Economics Review 2012 2:5
  27. Invasive (IPD, defined as detection of pneumococci in sterile body fluids like meningitis or bacteremic pneumonia) and non-invasive Streptococcus pneumoniae infections (i.e. non-bacteremic pneumonia, otitis media...

    Authors: Alexander Kuhlmann, Ulrike Theidel, Mathias W Pletz and J-Matthias Graf von der Schulenburg
    Citation: Health Economics Review 2012 2:4
  28. Opioid addiction is a worldwide problem. Agonist opioid treatment (AOT) is the most widespread and frequent pharmacotherapeutic approach. Methadone has been the most widely used AOT, but buprenorphine, a parti...

    Authors: Jose Martinez-Raga, Francisco Gonzalez-Saiz, Julian Oñate, Itziar Oyagüez, Eliazar Sabater and Miguel A Casado
    Citation: Health Economics Review 2012 2:3
  29. In April 2008, the specialization in departments of obstetrics and gynecology was conducted in Sennan area of Osaka prefecture in Japan, which aims at solving the problems of regional provision of obstetrical ...

    Authors: Junyi Shen, On Fukui, Hiroyuki Hashimoto, Takako Nakashima, Tadashi Kimura, Kenichiro Morishige and Tatsuyoshi Saijo
    Citation: Health Economics Review 2012 2:2

Annual Journal Metrics

  • 2022 Citation Impact
    2.4 - 2-year Impact Factor
    2.8 - 5-year Impact Factor
    1.204 - SNIP (Source Normalized Impact per Paper)
    0.836 - SJR (SCImago Journal Rank)

    2023 Speed
    11 days submission to first editorial decision for all manuscripts (Median)
    220 days submission to accept (Median)

    2023 Usage 
    483 Altmetric mentions